BAMPSL Securities is a non-banking financial company that primarily trades and invests in equity shares and provides short-term and long-term loans to various clients.
The company operates in a highly commoditized financial services and trading sector with no evidence of cost advantages or proprietary access to capital, as reflected by extremely low returns on capital (ROCE 0.8%) and a lack of pricing power.
Management reinvests earnings into a mix of quoted and unquoted securities and capital advances, but these investments have historically generated returns significantly below the cost of capital, failing to create shareholder value.
The investment collapsed as the regulatory net tightened around the company's persistent compliance failures. The SEBI surveillance measures, which were already visible in 2025, eventually led to a full trading suspension or delisting as the management failed to rectify basic filing deficiencies and related-party disclosure gaps. Meanwhile, the massive capital advances sitting on the balance sheet were never recovered or were written off, revealing that the reported book value was largely illusory. With returns on capital already near zero, the business simply bled out through administrative costs and tax litigations, leaving shareholders with a shell of a company that had no viable path to generating cash.
RichFakir rates BAMPSL Securities Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, BAMPSL Securities Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on BAMPSL Securities Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of BAMPSL Securities Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →